Medical Crossfire®: Meeting the Challenges of Alzheimer''s Disease with Early Diagnosis and Multifaceted Disease Management

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Biogen and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


This activity is provided by Physicians’ Education Resource®, LLC.

Dates of Certification: December 28, 2017-December 28, 2018

Chair/Moderator

Richard S. Isaacson, MD
Director of the Alzheimer’s Prevention Clinic
Weill Cornell Memory Disorders Program
Director of the Neurology Residency Training Program
Weill Cornell Medical College/New York-Presbyterian Hospital
New York, New York
Disclosure: Consultant: 23 and Me, Eli, Lilly, Neurotrack

Faculty

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
Alzheimer’s Drug Discovery Foundation
Clinical Professor of Geriatric Medicine and Neuroscience
The Icahn School of Medicine at Mount Sinai
New York, New York
Disclosure: Consultant: Axovant Sciences, Eli Lilly, Merck & Co., Otsuka
 
James Taylor
Patient Advocate
Disclosure: No relevant financial relationships with commercial interests
 
Geri Taylor
Patient Advocate
Disclosure: No relevant financial relationships with commercial interests

Activity Overview

Despite the substantial progress made in understanding and treating Alzheimer’s disease in recent years, no disease modifying treatments are available such that care is limited to treatment of dementia symptoms and pursuit of the best possible quality of life. During this Medical Crossfire®, expert faculty will engage in a multidisciplinary roundtable discussion that includes a neurologist and a geriatrician. A patient advocate and early-stage patient give voice to the many facets of lifestyle management and future planning.  This activity provides key guidance for diagnosing and treating Alzheimer’s disease and promoting the collaborative care between primary care providers, geriatricians, neurologists and psychiatrists who not only have the patients’ needs at heart, but include caregivers as a member of the multidisciplinary team, steadfastly involved in decision-making processes.

Target Audience

This activity is directed to primary care providers, neurologists, geriatric specialists, and psychiatrists who treat patients with Alzheimer’s Disease. Nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of Alzheimer’s disease are invited to participate.

Educational Objectives

At the completion of this activity, you should be better prepared to:
  • Describe neurodegenerative changes that are considered the hallmarks of Alzheimer’s disease (AD)
  • Describe screening and diagnostic tools for the early identification of individuals with AD
  • Describe emerging biomarkers for earlier and more accurate diagnosis
  • Select appropriate therapy for patients with AD to slow disease progression and improve patient and caregiver quality of life (QoL)
  • Describe lifestyle modifications that can improve QoL for patients and caregivers

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5  AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI. Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
 
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Program Resources

Alzheimer’s Association
www.alz.org    

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com
 

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox


Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari


Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh
 
For questions about this Internet CE activity, please contact: CEINFO@permedical.com
Privacy Policy and Terms of Use Information: http://www.gotoper.com/privacy






Become a Member

Forgot Password?
Filter By